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Abstract
Leptin is a multifunctional hormone produced mainly by the adipose
tissue and involved in the regulation of food intake and energy
balance. In addition, leptin can stimulate mitogenic and angiogenic
processes in peripheral organs. Because leptin levels are elevated
in obese individuals and excess body weight has been shown to
increase breast cancer risk in postmenopausal women, attempts
have been made to evaluate whether leptin can promote breast
cancer. Data obtained in cell and animal models and analyses of
human breast cancer biopsies indeed suggest such an involvement.
Furthermore, a recent report clearly shows that targeting leptin
signaling may reduce mammary carcinogenesis. Thus, leptin should
become a new attractive target in breast cancer.
Obesity has been shown to increase breast cancer risk in
postmenopausal women by 30% to 50% [1]. Moreover, high
body mass index has been found to be significantly
associated with an increased risk of inflammatory breast
cancer in both premenopausal and postmenopausal
populations [1]. In a very recent report on breast cancer,
obese patients presented with larger, more advanced tumors
and aggressive cancer pathological features, including lymph
node metastases, advanced tumor stage, and high grade [2].
Despite this suggestive epidemiological evidence, the
molecular mechanisms of obesity-induced breast carcino-
genesis are not clear. One hypothesis is that high levels of
biologically active substances produced by fat cells
(adipokines) could promote breast cancer development.
Indeed, adipose tissue is a source of estrogens, insulin and
insulin-like growth factors, all of which are believed to be
involved in mammary tumorigenesis and have been extensively
evaluated as breast cancer markers and therapeutic targets.
However, the possible role of the most prominent adipokine,
leptin (obesity protein), is just being recognized.
Leptin was first described as a neurohormone whose primary
function is to regulate energy balance and food intake in the
hypothalamus. Subsequent studies found that leptin can
modulate several processes in the peripheral organs, such as
immune response, fertility, and hematopoiesis. On a cellular
level, leptin has been found to act as a mitogen, metabolic
regulator, and motogenic and pro-angiogenic factors [1,3]. In
addition, new evidence suggests that leptin could be involved
in tumorigenesis, especially in the development of breast,
colorectal and prostate cancers [1].
In several breast cancer cell models, leptin has been shown
to induce proliferation, survival and anchorage-independent
growth. These leptin activities are mediated through the
long/signaling form of the leptin receptor (ObRL) that, upon
leptin binding, can stimulate the Jak/STAT3, ERK1/2, and
phosphoinositide 3-kinase pathways as well as induce cyclin
D1 expression and retinoblastoma protein hyperphosphory-
lation [1,4].
In addition to its own effects, leptin crosstalks with other
signaling systems in breast cancer cells. For instance, leptin-
activated ObRL has been shown to transactivate HER2/neu
[5]. Leptin can also increase the expression of vascular
endothelial growth factor (VEGF) [1]. Furthermore, leptin is a
potent modulator of estrogen receptor (ER)α. First, it
stimulates aromatase expression and, as a consequence,
elevates estrogen levels via increased aromatization of
androgens. Next, it can activate ERα and ERα-dependent
transcription in a ligand-independent manner [6]. Finally, in
the presence of the antiestrogen ICI182,780 (Faslodex),
leptin stabilizes ERα, interfering with the proteasome-
ubiquitin pathways of ERα degradation. All these data
suggest that high leptin levels might impede different breast
cancer therapies, including those targeting ERα, HER2/neu
or the VEGF receptor.
The relevance of leptin signaling in breast tumorigenesis is
reinforced by the fact that the expression of ObR mRNA and
protein has been documented in breast cancer biopsies.
Most importantly, ObRL as well as other ObR isoforms are
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overexpressed in breast cancer in comparison to normal
mammary epithelium and benign mammary tumors [1,7,8].
What is the origin of leptin that acts upon breast cancer
cells? Until now, the association between circulating leptin
levels and breast cancer or breast cancer risk has not been
clear. Some authors found that serum leptin was associated
with breast cancer regardless of the menopausal status,
while others described a negative correlation between leptin
and breast cancer in the premenopausal, but not post-
menopausal, group [1]. Other reports claimed that circulating
leptin is not associated with breast cancer or breast cancer
risk in pre- or postmenopausal women [1]. The inconsistent
data obtained with systemic leptin as a breast cancer marker
could be, at least in part, explained by differences in detection
techniques or by differences in sample preparation where
some influencing factors, such as food intake and circadian
rhythm, were not controlled. Clearly, better-controlled studies
are needed to unequivocally establish whether serum leptin is
associated with breast cancer etiology.
Regardless of the impact of circulating leptin, recent studies
suggest that breast carcinogenesis could be induced by
overabundance of locally produced leptin. The analysis of
approximately 300 biopsies revealed that, similar to ObR,
leptin is overexpressed in breast cancer, while it is absent or
expressed at very low levels in normal epithelium or benign
tumors [7,8]. Moreover, the expression of leptin positively
correlated with ObR, suggesting the existence of an
autocrine leptin loop [7,8]. Why do breast cancer cells
overexpress the leptin/ObR system? Our preliminary data
suggest that both markers can be induced by high levels of
insulin, estrogen or insulin-like growth factor-I, the factors that
are increased in obese individuals [7].
Further insight into leptin involvement in mammary carcino-
genesis is provided by studies in animal models. Earlier
research using rodents suggested increased body weight as
a risk factor in the development of both spontaneous and
chemically induced mammary tumors [1]. Recent studies
using transforming growth factor-α transgenic mice implied
that leptin and ObRL might be necessary for the development
of mammary tumors [1]. Finally, a recent report by Gonzalez
and colleagues [9] provides evidence that leptin contributes
to and is required for mammary tumor development in a
mouse syngeneic model. Specifically, leptin induced 4T1
tumor cell growth and stimulated the expression of VEGF/
VEGF receptor 2. These effects were inhibited by pre-
treatment of animals with leptin receptor antagonists.
Thus, the existing data suggest that the leptin/ObR system is
specifically overexpressed in cancer and might be involved in
breast tumorigenesis. However, several questions remain
unanswered. For instance, despite the fact that leptin
expression can be stimulated by obesity-related factors or
conditions, the causal link between overall obesity or upper
body obesity in humans and leptin expression in breast
tumors has not been established. Similarly, the impact of
obesity and leptin (systemic and local) on the response to
breast cancer therapy is not known. Finally, if the leptin/ObR
system proves to be truly involved in breast cancer
development and progression, the efficacy of leptin targeting
drugs in breast cancer management should be explored.
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